Emavusertib HCl | CAS#2376399-42-5 | IRAK4/FLT3 inhibitor| MedKoo

MedKoo Cat#: 124415 | Name: Emavusertib HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Emavusertib, also known as CA-4948 is a potent IRAK4/FLT3 inhibitor with anti-tumor activity. CA-4948 demonstrated good cellular activity in ABC DLBCL and AML cell lines. CA-4948 demonstrated moderate to high selectivity in a panel of 329 kinases as well as exhibited desirable ADME and PK profiles including good oral bioavailability in mice, rat, and dog and showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation.

Chemical Structure

Emavusertib HCl

CAS#2376399-42-5 (HCl)

Theoretical Analysis

MedKoo Cat#: 124415

Name: Emavusertib HCl

CAS#: 2376399-42-5 (HCl)

Chemical Formula: C24H26ClN7O5

Exact Mass: 527.1700

Molecular Weight: 527.97

Elemental Analysis: C, 54.60; H, 4.96; Cl, 6.71; N, 18.57; O, 15.15

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

2376399-39-0 (maleate) 1801344-14-8 (free base) 2376399-42-5 (HCl) 1801343-74-7 (CA4948-Analog) 2376399-40-3(mesylate) 2376399-41-4 (tosylate) 2376399-38-9 (phosphate)

Synonym

Emavusertib Hydrochloride; Emavusertib HCl; CA-4948; CA 4948; CA4948;

IUPAC/Chemical Name

N-{5-[(3R)-3-hydroxypyrrolidin-1-yl]-2-(morpholin-4-yl)[1,3]oxazolo[4,5-b]pyridin-6-yl}-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide hydrochloride

InChi Key

OUXHHDXWNFNMQC-PKLMIRHRSA-N

InChi Code

InChI=1S/C24H25N7O5.ClH/c1-14-10-15(2-4-25-14)23-27-18(13-35-23)22(33)26-17-11-19-20(28-21(17)31-5-3-16(32)12-31)29-24(36-19)30-6-8-34-9-7-30;/h2,4,10-11,13,16,32H,3,5-9,12H2,1H3,(H,26,33);1H/t16-;/m1./s1

SMILES Code

O=C(C1=COC(C2=CC(C)=NC=C2)=N1)NC3=C(N4C[C@H](O)CC4)N=C5C(OC(N6CCOCC6)=N5)=C3.[H]Cl

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 527.97 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Xu J, Qian Q, Xia M, Wang X, Wang H. Trichlorocarban induces developmental and immune toxicity to zebrafish (Danio rerio) by targeting TLR4/MyD88/NF-κB signaling pathway. Environ Pollut. 2021 Jan 10;273:116479. doi: 10.1016/j.envpol.2021.116479. Epub ahead of print. PMID: 33460871. 2: Gummadi VR, Boruah A, Ainan BR, Vare BR, Manda S, Gondle HP, Kumar SN, Mukherjee S, Gore ST, Krishnamurthy NR, Marappan S, Nayak SS, Nellore K, Balasubramanian WR, Bhumireddy A, Giri S, Gopinath S, Samiulla DS, Daginakatte G, Basavaraju A, Chelur S, Eswarappa R, Belliappa C, Subramanya HS, Booher RN, Ramachandra M, Samajdar S. Discovery of CA-4948, an Orally Bioavailable IRAK4 Inhibitor for Treatment of Hematologic Malignancies. ACS Med Chem Lett. 2020 Oct 14;11(12):2374-2381. doi: 10.1021/acsmedchemlett.0c00255. PMID: 33335659; PMCID: PMC7734642. 3: Wiese MD, Manning-Bennett AT, Abuhelwa AY. Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs. 2020 May;29(5):475-482. doi: 10.1080/13543784.2020.1752660. Epub 2020 Apr 17. PMID: 32255710. 4: McElroy WT. Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018). Expert Opin Ther Pat. 2019 Apr;29(4):243-259. doi: 10.1080/13543776.2019.1597850. Epub 2019 Mar 29. PMID: 30916602.